全文获取类型
收费全文 | 116篇 |
免费 | 10篇 |
国内免费 | 2篇 |
专业分类
基础医学 | 14篇 |
临床医学 | 10篇 |
内科学 | 50篇 |
神经病学 | 4篇 |
特种医学 | 15篇 |
外科学 | 28篇 |
综合类 | 1篇 |
预防医学 | 1篇 |
肿瘤学 | 5篇 |
出版年
2022年 | 3篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 3篇 |
2018年 | 2篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 9篇 |
2014年 | 9篇 |
2013年 | 9篇 |
2012年 | 13篇 |
2011年 | 11篇 |
2010年 | 1篇 |
2009年 | 3篇 |
2008年 | 2篇 |
2007年 | 4篇 |
2006年 | 2篇 |
2005年 | 13篇 |
2004年 | 24篇 |
2003年 | 8篇 |
2002年 | 4篇 |
2001年 | 1篇 |
排序方式: 共有128条查询结果,搜索用时 15 毫秒
21.
Chourmouzios A Arampatzis Pedro A Lemos Angela Hoye Francesco Saia Kengo Tanabe Willem J van der Giessen Pieter C Smits Eugene McFadden Pim de Feyter Patrick W Serruys 《Catheterization and cardiovascular interventions》2004,62(3):292-6; discussion 297
The effectiveness of sirolimus-eluting stent (SES) implantation in patients treated electively for left main (LM) stenoses has not been yet ascertained. The present study reports on the clinical and angiographic outcome of 16 consecutive patients treated electively for de novo stenoses in the LM. The impact of SES implantation on major adverse cardiac events was evaluated. Mean age was 65 +/- 11 years. Unprotected LM was present in nine (56%), and eight patients (50%) received stents extending into both the left anterior descending and circumflex arteries for stenoses of the distal left main bifurcation. In-house mortality and reintervention rate was zero. One patient developed a non-Q-wave myocardial infarction related to the index procedure. At 1-year clinical follow-up, there were no deaths or further myocardial infarctions; one (6%) patient required target lesion revascularization. A total of 12 patients (75%) underwent 6-month angiographic follow-up with a late lumen loss of 0.04 +/- 0.65 mm and one focal restenosis (8% of patients). Elective SES implantation for LM disease was associated with zero mortality and a very low incidence of additional major adverse events at 1 year. 相似文献
22.
Lemos PA Lee CH Degertekin M Saia F Tanabe K Arampatzis CA Hoye A van Duuren M Sianos G Smits PC de Feyter P van der Giessen WJ van Domburg RT Serruys PW 《Journal of the American College of Cardiology》2003,41(11):2093-2099
OBJECTIVES: This study evaluated the early outcomes of patients with acute coronary syndromes (ACS) treated with sirolimus-eluting stents (SES). BACKGROUND: The safety of SES implantation in patients with a high risk for early thrombotic complications is currently unknown. METHODS: Sirolimus-eluting stents have been utilized as the device of choice for all percutaneous procedures in our institution, as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. After four months of enrollment, 198 patients with ACS had been treated exclusively with SES (64% of those treated in the period) and were compared with a control group composed of 301 consecutive patients treated with bare stents in the same time period immediately before this study. The incidence of major adverse cardiac events (MACE) during the first month was evaluated (death, nonfatal myocardial infarction [MI], or re-intervention). RESULTS: Compared with control patients, patients treated with SES had more primary angioplasty (95% vs. 77%; p < 0.01), more bifurcation stenting (13% vs. 5%; p < 0.01), less previous MI (28% vs. 45%; p < 0.01), and less glycoprotein IIb/IIIa inhibitor utilization (27% vs. 42%; p < 0.01). The 30-day MACE rate was similar between both groups (SES 6.1% vs. control patients 6.6%; p = 0.8), with most complications occurring during the first week. Stent thrombosis occurred in 0.5% of SES patients and in 1.7% of control patients (p = 0.4). In multivariate analysis, SES utilization did not influence the incidence of MACE (odds ratio 1.0 [95% confidence interval: 0.4 to 2.2]; p = 0.97). CONCLUSIONS: Sirolimus-eluting stent implantation for patients with ACS is safe, with early outcomes comparable with bare metal stents. 相似文献
23.
24.
25.
26.
Lida Mademli Adamantios Arampatzis Kiros Karamanidis 《European journal of applied physiology》2008,103(3):295-306
Many studies report that muscle strength loss may alter the human system’s capacity to generate rapid force for balance corrections
after perturbations, leading to deficient recovery behaviours. Yet little is known regarding the effect of modifications in
the neuromuscular system induced by fatigue on dynamic stability control during postural perturbations. This study investigates
the effect of muscle strength decline induced by fatiguing contractions on the dynamic stability control of young and older
adults during forward falls. Eleven young and eleven older male adults had to regain balance after sudden falls before and
after submaximal fatiguing knee extension–flexion contractions. Young subjects had a higher margin of stability than older
ones before and after the fatiguing task. This reflects their enhanced ability in using mechanisms for maintaining dynamic
stability (i.e. a greater base of support). The margin of stability, the boundary of the base of support and the position
of the extrapolated centre of mass, remained unaffected by the reduction in muscle strength induced by the fatiguing contractions,
indicating an appropriate adjustment of the motor commands to compensate the deficit in muscle strength. Both young and older
adults were able to counteract the decreased horizontal ground reaction forces after the fatiguing task by flexing their knee
to a greater extent, leading to similar decreases in the horizontal velocity of centre of mass as in the pre fatigue condition.
The results demonstrate the ability of the central nervous system to rapidly modify the execution of postural corrections
including mechanisms for maintaining dynamic stability. 相似文献
27.
Michail?Kornaropoulos Demetrios?MorisEmail author Eliza?W.?Beal Marinos?C.?Makris Apostolos?Mitrousias Athanasios?Petrou Evangelos?Felekouras Adamantios?Michalinos Michail?Vailas Dimitrios?Schizas Alexandros?Papalampros 《Surgical endoscopy》2017,31(11):4382-4392
Background
Pancreaticoduodenectomy (PD) is a complex operation with high perioperative morbidity and mortality, even in the highest volume centers. Since the development of the robotic platform, the number of reports on robotic-assisted pancreatic surgery has been on the rise. This article reviews the current state of completely robotic PD.Materials and Methods
A systematic literature search was performed including studies published between January 2000 and July 2016 reporting PDs in which all procedural steps (dissection, resection and reconstruction) were performed robotically.Results
Thirteen studies met the inclusion criteria, including a total of 738 patients. Data regarding perioperative outcomes such as operative time, blood loss, mortality, morbidity, conversion and oncologic outcomes were analyzed. No major differences were observed in mortality, morbidity and oncologic parameters, between robotic and non-robotic approaches. However, operative time was longer in robotic PD, whereas the estimated blood loss was lower. The conversion rate to laparotomy was 6.5–7.8%.Conclusions
Robotic PD is feasible and safe in high-volume institutions, where surgeons are experienced and medical staff are appropriately trained. Randomized controlled trials are required to further investigate outcomes of robotic PD. Additionally, cost analysis and data on long-term oncologic outcomes are needed to evaluate cost-effectiveness of the robotic approach in comparison with the open technique.28.
Tereza Buchtova Zdenek Skrott Katarina Chroma Jiri Rehulka Petr Dzubak Marian Hajduch David Lukac Stefanos Arampatzis Jiri Bartek Martin Mistrik 《Molecular oncology》2022,16(7):1541
Disulfiram (DSF), an established alcohol‐aversion drug, is a candidate for repurposing in cancer treatment. DSF’s antitumor activity is supported by preclinical studies, case reports, and small clinical trials; however, ongoing clinical trials of advanced‐stage cancer patients encounter variable results. Here, we show that one reason for the inconsistent clinical effects of DSF may reflect interference by other drugs. Using a high‐throughput screening and automated microscopy, we identify cannabidiol, an abundant component of the marijuana plant used by cancer patients to mitigate side effects of chemotherapy, as a likely cause of resistance to DSF. Mechanistically, in cancer cells, cannabidiol triggers the expression of metallothioneins providing protective effects by binding heavy metal‐based substances including the bis‐diethyldithiocarbamate‐copper complex (CuET). CuET is the documented anticancer metabolite of DSF, and we show here that the CuET’s anticancer toxicity is effectively neutralized by metallothioneins. Overall, this work highlights an example of undesirable interference between cancer therapy and the concomitant usage of marijuana products. In contrast, we report that insufficiency of metallothioneins sensitizes cancer cells toward CuET, suggesting a potential predictive biomarker for DSF repurposing in oncology. 相似文献
29.
Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species 总被引:3,自引:0,他引:3
Arampatzis S Kadereit B Schuster D Balazs Z Schweizer RA Frey FJ Langer T Odermatt A 《Journal of molecular endocrinology》2005,35(1):89-101
11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1), catalyzing the intracellular activation of cortisone to cortisol, is currently considered a promising target to treat patients with metabolic syndrome; hence, there is considerable interest in the development of selective inhibitors. For preclinical tests of such inhibitors, the characteristics of 11beta-HSD1 from the commonly used species have to be known. Therefore, we determined differences in substrate affinity and inhibitor effects for 11beta-HSD1 from six species. The differences in catalytic activities with cortisone and 11-dehydrocorticosterone were rather modest. Human, hamster and guinea-pig 11beta-HSD1 displayed the highest catalytic efficiency in the oxoreduction of cortisone, while mouse and rat showed intermediate and dog the lowest activity. Murine 11beta-HSD1 most efficiently reduced 11-dehydrocorticosterone, while the enzyme from dog showed lower activity than those from the other species. 7-ketocholesterol (7KC) was stereospecifically converted to 7beta-hydroxycholesterol by recombinant 11beta-HSD1 from all species analyzed except hamster, which showed a slight preference for the formation of 7alpha-hydroxycholesterol. Importantly, guinea-pig and canine 11beta-HSD1 displayed very low 7-oxoreductase activities. Furthermore, we demonstrate significant species-specific variability in the potency of various 11beta-HSD1 inhibitors, including endogenous compounds, natural chemicals and pharmaceutical compounds. The results suggest significant differences in the three-dimensional organization of the hydrophobic substrate-binding pocket of 11beta-HSD1, and they emphasize that species-specific variability must be considered in the interpretation of results obtained from different animal experiments. The assessment of such differences, by cell-based test systems, may help to choose the appropriate animal for safety and efficacy studies of novel potential drug candidates. 相似文献
30.
Ron T van Domburg Pedro A Lemos Johanna J M Takkenberg Tommy K K Liu Lex A van Herwerden Chourmouzios A Arampatzis Pieter C Smits Joost Daemen Angeliek C Venema Patrick W Serruys Ad J J C Bogers 《European heart journal》2005,26(7):675-681
AIMS: Sirolimus-eluting stents (SES) have recently been shown to reduce restenosis in selected patients. The impact of this new stent on the use of coronary bypass graft (CABG) surgery or percutaneous coronary intervention (PCI) in clinical practice is yet unknown. Therefore, we investigated the impact of SES on the clinical practice of CABG and PCI in a series of unselected consecutive patients. METHODS AND RESULTS: Between April and October 2002, a policy of SES implantation for all procedures has been instituted in our hospital. In total, 798 patients were referred to PCI and 275 to CABG (SES group). A control group was composed of all interventions (806 PCI and 314 CABG) performed during the preceding 6 months (pre-SES). The main outcome was the occurrence of major adverse cardiac events (MACE) at 15 months. In the SES era, a significant shift was noted in the PCI group towards more multi-vessel stenting (28 vs. 24%; P<0.05), more bifurcation stenting (18 vs. 7%; P<0.0001), and the use of more stents (1.9 vs. 1.5; P<0.05). In the PCI elective patients, a shift was noted towards more three-vessel disease (pre-SES: 16% vs. SES: 23%; P=0.02). Furthermore, we observed a shift in the CABG group towards more impaired LV function (pre-SES: 34% vs. SES: 41%; P=0.02) and towards more three-vessel disease (pre-SES: 67% vs. SES: 75%; P=0.03). Overall, the cumulative MACE percentages at 1 year after coronary revascularization (PCI and CABG combined) decreased from 16.8 to 13.8% (P=0.03). The cumulative MACE percentages in the pure SES group and the pre-SES bare metal stent group at 12 months were 15.6 and 19.8%, respectively (P<0.01). CONCLUSION: The introduction of the SES has certainly had an impact on the treatment strategy of coronary artery disease (CAD). Increased use of these stents allows more complex coronary anatomy to be treated by PCI, and results in lower repeat revascularization rates. 相似文献